Showing results (151-160 of 601) with videos related to
Sort By:
Pageof 61
Blood|June 10, 2011
Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cellsMin Tang, Mithat Gonen, Alfonso Quintas-Cardama, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 10, 2012
Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancerMarkus Riester, Jennifer M Taylor, Andrew Feifer, et al.Cell Cycle (Georgetown, Tex.)|October 5, 2010
Evolutionary dynamics of two related malignant plasma cell linesDavid Dingli, Bonnie K Arendt, Zeljko Bajzer, et al.Leukemia Research|November 18, 2005
Microcytosis in agnogenic myeloid metaplasia: prevalence and clinical correlatesAyalew Tefferi, David Dingli, Chin-Yang Li, et al.Cancer|August 17, 2005
Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasiaAyalew Tefferi, David Dingli, Chin-Yang Li, et al.Hematology (Amsterdam, Netherlands)|February 9, 2026
Switching patients with PNH from pegcetacoplan to iptacopan: a case seriesMark Orland, Carmelo Gurnari, Srinivasa Sanikommu, et al.Haematologica|July 2, 2013
Schnitzler syndrome: an under-diagnosed clinical entityTania Jain, Chetan P Offord, Robert A Kyle, et al.Journal of Comparative Effectiveness Research|September 1, 2023
The cost-effectiveness of pegcetacoplan in complement treatment-naïve adults with paroxysmal nocturnal hemoglobinuria in the USAJesse Fishman, Koo Wilson, Aleksandra Drzewiecka, et al.Drugs in R&D|May 10, 2024
Normalization of Hemoglobin, Lactate Dehydrogenase, and Fatigue in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with PegcetacoplanBrian P Mulherin, Michael Yeh, Mohammed Al-Adhami, et al.BMC Cancer|May 1, 2019
How many samples are needed to infer truly clonal mutations from heterogenous tumours?Luka Opasic, Da Zhou, Benjamin Werner, et al.Pageof 61